Effective neoadjuvant immunotherapy and chemotherapy in stage IIIA adenosquamous carcinoma of the lung with a complete response and surgical success: A case report

Song,Chen; Nie,Yuhui; Liu,Tianzi; Peng,Xintong; Liu,Jing; Zhou,Ziwen; Huang,Yan

doi:10.3892/ol.2024.14448

Effective neoadjuvant immunotherapy and chemotherapy in stage IIIA adenosquamous carcinoma of the lung with a complete response and surgical success: A case report

Authors:
- Chen Song
- Yuhui Nie
- Tianzi Liu
- Xintong Peng
- Jing Liu
- Ziwen Zhou
- Yan Huang
View Affiliations

Affiliations: Department of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China, Department of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong 261053, P.R. China, Department of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261041, P.R. China, Department of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261041, P.R. China
Published online on: May 14, 2024 https://doi.org/10.3892/ol.2024.14448
Article Number: 314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There has been rapid advancement in the development of neoadjuvant therapy for non‑small cell lung cancer (NSCLC), which holds great promise as an effective treatment strategy. Some clinical trials have confirmed that immunotherapy in combination with chemotherapy can be a recommended first‑line regimen for neoadjuvant treatment of NSCLC. The present study describes the case of a male patient aged 65 years who was diagnosed with stage IIIA (cT2N2M0) adenosquamous carcinoma of the lung. After the administration of two cycles of neoadjuvant immunotherapy (sintilimab) in combination with chemotherapy, stable disease was observed in the primary tumor, whereas partial remission was detected in the mediastinal lymph nodes based on imaging assessment. The patient underwent an immediate upper lobectomy of the left lung. Pathological analysis revealed a complete response in the primary lesion, with only minimal presence of tumor cells observed in the lymph nodes surrounding the mediastinum and bronchi. This indicated that the present neoadjuvant therapy could be used in the treatment of stage III adenosquamous lung carcinoma; however, to conclusively determine its efficacy, further studies targeting this specific cancer type are essential.

View Figures

View References

1	Huang C, Xu J and Li Z: Research Progress of Cancer-associated Fibroblasts in Lung Cancer]. Zhongguo Fei Ai Za Zhi. 23:267–273. 2020.(In Chinese). PubMed/NCBI
2	Marx A, Chan JK, Coindre JM, Detterbeck F, Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, et al: The 2015 World health organization classification of tumors of the thymus: Continuity and changes. J Thorac Oncol. 10:1383–1395. 2015. View Article : Google Scholar : PubMed/NCBI
3	Liu Y, Zhu Y, Bai L, Chen F, Wang J and Guo Y: Adenocarcinomatous-predominant subtype associated with a better prognosis in adenosquamous lung carcinoma. BMC Cancer. 20:5202020. View Article : Google Scholar : PubMed/NCBI
4	Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: Introduction to The 2015 World health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
5	Filosso PL, Ruffini E, Asioli S, Giobbe R, Macri L, Bruna MC, Sandri A and Oliaro A: Adenosquamous lung carcinomas: A histologic subtype with poor prognosis. Lung Cancer. 74:25–29. 2011. View Article : Google Scholar : PubMed/NCBI
6	Maeda H, Matsumura A, Kawabata T, Suito T, Kawashima O, Watanabe T, Okabayashi K and Kubota I; Japan National Hospital Organization Study Group for Lung Cancer, : Adenosquamous carcinoma of the lung: Surgical results as compared with squamous cell and adenocarcinoma cases. Eur J Cardiothorac Surg. 41:357–361. 2012. View Article : Google Scholar : PubMed/NCBI
7	Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
8	Zhang L, Mai W, Jiang W and Geng Q: Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 10:5945582020. View Article : Google Scholar : PubMed/NCBI
9	Jiang J, Wang Y, Gao Y, Sugimura H, Minervini F, Uchino J, Halmos B, Yendamuri S, Velotta JB and Li M: Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: A systematic review and meta-analysis. Transl Lung Cancer Res. 11:277–294. 2022. View Article : Google Scholar : PubMed/NCBI
10	Detterbeck FC, Boffa DJ, Kim AW and Tanoue LT: The Eighth Edition lung cancer stage classification. Chest. 151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
11	Huber RM, Kauffmann-Guerrero D, Hoffmann H and Flentje M: New developments in locally advanced nonsmall cell lung cancer. Eur Respir Rev. 30:2002272021. View Article : Google Scholar : PubMed/NCBI
12	Sun C, Liu Y, Zhang P, Wang X, Xu Y, Lin X, Ma X, Guo Y, Qiu S, Shao G, et al: Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: A single-arm, phase 2 trial. J Cancer Res Clin Oncol. 149:819–831. 2023. View Article : Google Scholar : PubMed/NCBI
13	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
14	Thai AA, Solomon BJ, Sequist LV, Gainor JF and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
15	Zhang N, Chen S, Guo L and Chen X: A case report of right upper lung adenosquamous carcinoma resection following neoadjuvant targeted therapy. Ann Palliat Med. 10:4987–4993. 2021. View Article : Google Scholar : PubMed/NCBI
16	Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 112:200–215. 2017. View Article : Google Scholar : PubMed/NCBI
17	Kang J, Zhang C and Zhong WZ: Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Commun (Lond). 41:287–302. 2021. View Article : Google Scholar : PubMed/NCBI
18	Xie J, Wu X, Wu J, Huang F and Xu L: Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer. Oncol Lett. 24:4252022. View Article : Google Scholar : PubMed/NCBI
19	Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI
20	Shao M, Yao J, Wang Y, Zhao L, Li B, Li L, Wu Z, Chen Z, Fan J and Qiu F: Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: NeoSCORE trial. Signal Transduct Target Ther. 8:1462023. View Article : Google Scholar : PubMed/NCBI
21	Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al: Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI
22	Expert Committee on Quality Control of Lung Cancer, National Quality Control Center for Cancer: Expert consensus on the pathological evaluation of neoadjuvant therapy efficacy for non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi. 50:1002–1007. 2021.(In Chinese). PubMed/NCBI
23	Song P, Zhang J, Shang C and Zhang L: Curative effect assessment of immunotherapy for non-small cell lung cancer: The ‘blind area’ of Immune Response Evaluation Criteria in Solid Tumors (iRECIST). Thorac Cancer. 10:587–592. 2019. View Article : Google Scholar : PubMed/NCBI
24	Fleming CA, McCarthy K, Ryan C, McCarthy A, O'Reilly S, O'Mahony D, Browne TJ, Redmond P and Corrigan MA: Evaluation of discordance in primary tumor and lymph node response after neoadjuvant therapy in breast cancer. Clin Breast Cancer. 18:e255–e261. 2018. View Article : Google Scholar : PubMed/NCBI
25	Wei J, Xiang J, Hao Y, Si J, Gu X, Xu M and Song Z: Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma. J Thorac Dis. 15:260–269. 2023. View Article : Google Scholar : PubMed/NCBI
26	Li C and Lu H: Adenosquamous carcinoma of the lung. Onco Targets Ther. 11:4829–4835. 2018. View Article : Google Scholar : PubMed/NCBI
27	Liu Y, Gao Z, Zhang C, Liu X, Liu Z, Lin X, Qian B, Jin F, Shao G and Yang Z: Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: A case report. Anticancer Drugs. 33:e784–e788. 2022. View Article : Google Scholar : PubMed/NCBI